by Barry101 | Jan 17, 2023 | Press Release, Uncategorized
Research collaboration will evaluate the potential of AIM’s Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of pancreatic cancerOCALA, Fla., Jan. 17, 2023 — AIM ImmunoTech Inc. (NYSE American:...
by Barry101 | Jan 9, 2023 | Press Release, Uncategorized
OCALA, Fla., Jan. 09, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and...
by Barry101 | Jan 5, 2023 | Press Release, Uncategorized
Live video webcast on Wednesday, January 18th at 11:00 AM ETOCALA, Fla., Jan. 05, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics...
by Barry101 | Dec 12, 2022 | Press Release, Uncategorized
Accomplished scientist with a diverse range of skills from general wet lab technique to company-wide operations managementOCALA, Fla., Dec. 12, 2022 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma...
by Barry101 | Dec 8, 2022 | Press Release, Uncategorized
Intranasal administration of Ampligen demonstrated to be well-tolerated Based on data generated to date, Ampligen could have potential as a prophylactic or early treatment against respiratory viral infections Data presented in poster presentation at the British...
